NRX Pharmaceuticals reported continued operating losses in Q1 2026 driven by clinical development and commercialization ramp-up within its CNS-focused portfolio. The company is advancing three main drug candidates—NRX-100, KETAFREE™, and NRX-101—targeting depression, bipolar disorder, and related neurological conditions through NMDA receptor modulation. Clinical milestones, including FDA communications on bioequivalence and Fast Track designations, underpin near-term growth expectations. Simultaneously, the firm is expanding its HOPE Therapeutics interventional psychiatry network integrating pharmacologic and device-based therapies, enhancing its differentiated care model. Funding constraints and regulatory uncertainties remain material risks to watch.